The Indian custom research and manufacturing segment is expected to reach a market size of $ 7.6 billion by 2012, with custom manufacturing leading the pack. The growth will be supported by, among other things, the high number of plants approved by the United States regulatory authority – the Food and Drug Administration; skilled manpower and the inherent cost advantages that enable India to capture a significant chunk of the current $ 67 billion global pharma outsourcing market.
The global outsourcing market is expected to grow at a compounded annual growth rate 12.6 percent during FY10-12 to reach a market size of $ 85 billion by FY12. In the same period, the Indian CRAM (custom research and manufacturing segment) is growing at about 41 percent. The growth of the outsourcing opportunity is being propelled by the loss of patent protection to the tune of $ 97 billion over 2011-2015; steady erosion in new product launches in relation to research spend and new launches not matching up to the earlier block-busters drugs (or medicines that gross sales of over $ 1 billion).This coupled with the increasing role of generics and pricing pressure played out in the developed nations have forced big pharma players to look for cost-containment measures to protect their bottom-line.
Key Indian companies operating in this space include Piramal Healthcare, Biocon Limited, Jubilant Life Sciences and Divi’s lab, who have displayed strong growth over the last few years, though concerns on economic slowdown has led to inventory rationalization by global pharma majors - thus leading to slowdown in growth during FY10 and H1 FY11.crackcrack
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: